Is trastuzumab a cost-effective treatment for breast cancer?

Younis, Tallal and Skedgel, Chris (2008) Is trastuzumab a cost-effective treatment for breast cancer? Expert Review of Pharmacoeconomics & Outcomes Research, 8 (5). pp. 433-442. ISSN 1473-7167

Full text not available from this repository. (Request a copy)

Abstract

Trastuzumab is a recombinant humanized monoclonal antibody that is currently approved for the treatment of HER2-neu-positive breast cancer. From a clinical perspective, it is an effective treatment with a relatively favorable benefit/risk profile. From an economic perspective, trastuzumab is an expensive treatment that is associated with high drug acquisition cost. Overall, it appears to provide reasonable 'value for money' (i.e., is cost-effective), especially in the adjuvant as opposed to the palliative setting. Trastuzumab's cost-effectiveness appears to be driven primarily by trastuzumab costs and the magnitude of benefit derived. Longer follow-up of clinical trials is, therefore, required to better estimate the long-term benefits associated with adjuvant trastuzumab, and its true cost-effectiveness in the treatment of HER2-neu-positive breast cancer.

Item Type: Article
Uncontrolled Keywords: breast cancer,clinical trial,cost-effectiveness,cost-utility,trastuzumab
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 04 Feb 2015 12:34
Last Modified: 21 Apr 2020 23:47
URI: https://ueaeprints.uea.ac.uk/id/eprint/51938
DOI: 10.1586/14737167.8.5.433

Actions (login required)

View Item View Item